Skip to main content
Premium Trial:

Request an Annual Quote

Sequentify Raises $7M, Exits Stealth Mode

NEW YORK – Israeli genomic sequencing company Sequentify emerged from stealth mode with $7 million in raised funds. Led by venture firm OurCrowd, the capital will be used to accelerate R&D, delivery, and go-to-market plans for the company, Sequentify said.

Founded in 2021 as a Weizmann Institute of Science spinout, Sequentify was built on a technology developed by cofounders Tamir Biezuner and Tom Fleischer at the laboratory of Liran Shlush.

The Rehovot, Israel-based startup claimed in a statement that its proprietary InfiniSeq technology condenses sample preparation time to "only 3.5 hours from DNA to sequencing, with one-tube reaction, full automation support, and dramatic cost reduction." The technology is also adjustable to most sequencing instruments and fits into any lab workflow, thus enabling full integration into laboratories, the firm said.

Based on the InfiniSeq platform, Sequentify's NGS products include COVID-19 surveillance, cancer diagnostics, and carrier screening, with multiple hospitals and labs as customers already, the company said.

"Sequentify enables DNA screening at scale with the goal of making genomics as common and affordable as testing for blood counts," Sequentify Cofounder and CEO Ophir Herbst said in a statement.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.